Ineffectiveness of sequential high dose methotrexate and 5-fluorouracil combined with epirubicin (FEMTX regimen) as a salvage therapy in advanced colorectal cancers and other gastro-intestinal tumors

Anticancer Research

Volumn 16, Issue 4 A, 1996, Pages 2063-2067

  Adenis, Antoine ^a   Leriche, Nathalie ^a   Pion, Jean Marc ^a   Vanlemmens, Laurence ^a   Bonneterre, Jacques ^a  

^a CENTRE OSCAR LAMBRET   (France)

Author keywords

Colorectal cancer; Epirubicin; Fluorouracil; Gastrointestinal cancer; Methotrexate

Indexed keywords

EPIRUBICIN; FLUOROURACIL; FOLINIC ACID; LOMUSTINE; METHOTREXATE; VINCRISTINE;

ADULT; ADVANCED CANCER; AGED; ALOPECIA; ANGINA PECTORIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CLINICAL ARTICLE; CLINICAL TRIAL; COLORECTAL CANCER; DIARRHEA; DIGESTIVE SYSTEM CANCER; DRUG EFFICACY; FATIGUE; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; PRIORITY JOURNAL; STOMATITIS; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; COLORECTAL NEOPLASMS; EPIRUBICIN; ESOPHAGEAL NEOPLASMS; FEMALE; FLUOROURACIL; GASTROINTESTINAL NEOPLASMS; HUMANS; LEUCOVORIN; MALE; METHOTREXATE; MIDDLE AGED; NEOPLASM METASTASIS; NEOPLASM STAGING; PALLIATIVE CARE; PANCREATIC NEOPLASMS; PILOT PROJECTS; SALVAGE THERAPY; TREATMENT FAILURE;

EID: 0029760498     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Findlay M, Cunningham D: Current advances in the treatment of gastrointestinal malignancy. Critical Reviews in Oncology/Hematology 14: 127- 152, 1993.
2. Klein HO: Long term results with FAMTX (5-fluorouracil, adriamycin, methotrexate) in advanced gastric cancer. Anticancer Res 9: 1025-1026, 1989.
3. Kelsen D, Atiq OT, Saltz L, Niedzwiecki D, Ginn D, Chapman D, Heelan R, Lightdale C, Vinciguerra V, Brennan M: FAMTX versus etoposide, doxorubicin, and cisplatin: a random assignment trial in gastric cancer. J Clin Oncol 10: 541-548, 1992.
4. Roelofs EJM, Wagener DJT, Conroy T, Wils J, Burghouts JT, Pickers M, De Graeff, Lalisang F, Paillot B: Phase II study of sequential high-dose methotrexate and 5-fluorouracil, alternated with epirubicin and cisplatin (FEMTX-P) in advanced gastric cancer. Ann Oncol 4: 426-428, 1993.
5. Wils JA, Klein HO, Wagener DJT, et al: Sequential high-dose methotrexate and 5fluorouracil combined with doxorubicin - a step ahead in the treatment of advanced gastric cancer: A trial of the European Organization for Research and Treatment of Cancer Gastrointestinal Tract Cooperative Group. J Clin Oncol 9: 827-831, 1991.
6. Garufi C, Brienza S, Bensmaine MA, Misset JL, Aschelter A, Pace R, Bertheault-Cvitkovic F, Terzoli E, Lévi F. Addition of oxaliplatin to chronomodulated 5-fluorouracil and folinic acid for reversal of acquired chemoresistance in patients with advanced colorectal cancer. J Clin Oncol 14: 446, 1995.
7. De Gramont A, Tournigand C, Louvet C, Lucchi E, Varette C, Raymond E, Gastiaburu J, Lecouturier S, Brienza S, Krulik M̃ High-dose folinic acid, 5-fluorouracil 48h-infusion and oxaliplatin in metastatic colorectal cancer. 6th International Congress on Anticancer chemotherapy, Paris, 2-5/02/1993, 0269, 114.
8. Bugat R, Rougier P, Douillard JY, Brunet R, Ychou M, Adenis A, Marty M, Seitz JF, Conroy T, Merrouche Y, Ganem G, Namer M, Burki F, Mousseau M, Mahjoubi M: Efficacy of irinotecan (CPT- 11) in patients with metastatic colorectal cancer after progression while receiving a FU-based chemotherapy. J Clin Oncol 14: 567, 1995.
9. Rougier P, Izzo J, Cvitkovic E, Ducreux M, Fandi A, Fabri MC, Kac J, Benhamed M, Lasser P, Armand JP: Interêt des perfusions continues à faible dose de 5-FU dans les cancers colorectaux métastatiques résistants au FU bolus ou à l'association FU + acide folinique. Gastroenterol Clin Biol 17: 65, 1993.
10. Mori A, Bertoglio S, Guglielmi A, Aschele C, Bolli E, Tixi L, Rosso R, Sobrero A Activity of continuous-infusion 5-fluorouracil in patients with advanced colorectal cancer clinically resistant to bolus 5-fluorouracil. Cancer Chemother Pharmacol 33: 179-180, 1993.
11. Pavlick AC, DelGaudio D, Harper H, Rosenbluth R, Pecora AL: Salvage therapy with continuous infusion 5-fluorouracil and alpha interferon in patients with colorectal cancer. J Clin Oncol 11: 565, 1992.
12. Weh HJ, Wilke HJ, Dierlamm J, Klaassen U, Siegmund R, Illiger HJ, Schalhorn A, Kreuser ED, Hilgenfeld U, Steinke B, Weber W, Burkhard O, Zoller A, Pfitzner J, Suber R, Kriebel R, Hossfeld DK: Weekly therapy with folinic acid and high-dose 5-fluorouracil 24-hour infusion in pretreated patients with metastatic colorectal carcinoma. Ann Oncol 5: 233-237, 1994.
13. Iaffaioli RV, Facchini G, Tortotiello A, Gesue G, Finizio A, Bucci L, Scaramellino G. Persico G: Navelbine plus FU and folinic acid in pretreated colorectal cancer patients. Preliminary data. Eur J Cancer 27: 99, 1993.
14. Ardalan B, Sridhar KS, Benedetto P, Richman S, Waldman S, Morrell L, Feun L, Savaraj N, Fodor M, Livingstone A: A phase I- II study of high-dose fluorouracil and high-dose leucovorin with low-dose phosphonacetyl-L-aspartic acid in patients with advanced malignancies. Cancer 68: 1242- 1246, 1991.
15. Poplin EA, LoRusso P, Lokich JJ, Gullo JJ, Leming PD, Schultz JJ, Veach SR, McCulloch W, Baker L, Schein P: Randomized clinical trial of mitomycin-C with or without pretreatment with WR-2721 in patients with advanced colorectal cancer. Cancer Chemother Pharmacol 33: 415-419, 1994.
16. Cascinu S, Fedeli A, Luzi-Fedeli S, Catalano G: Salvage chemotherapy in colorectal cancer patients with good performance status and young age after failure of 5fluorouracil-leucovorin combination. J Chemother 4: 46-49, 1992.
17. De Gramont A, Louvet C, Varette C, Demuynck B, Bennamoun M, Cady J, Grangé JD, Lagadec B, Maisani JE, Delfau S, Chazouilleres O, Loiseau JP, Seroka J, Krulik M: Reversal of resistance to high-dose folinic acid and 5-fluorouracil in metastatic colorectal cancer by hydroxyurea. J Clin Oncol 11: 527, 1992.
18. Lévi F, Perpoint B, Garufi C, Focan C, Chollet P, Depres-Brummer P, Zidani R, Brienza S, Itzhaki M, Iacobelli S, Kunstlinger J, Misset JL: Oxaliplatin activity against metastatic colorectal cancer. A phase II study of 5-day continuous venous infusion at circadian rhythm modulated rate. Eur J Cancer 29: 1280-1284, 1993.
19. Lévi F, Misset JL, Brienza S, Adam R, Metzger G, Itzakhi M, Caussanel JP, Kunstlinger F, Lecouturier S, Descorps-Declere A, Jasmin C, Bismuth H, Reinberg A: A chronopharmacologic phase II clinical trial with 5-fluorouracil, folinic acid, and oxaliplatin using an ambulatory multichannel programmable pump. Cancer 69: 893-900, 1992.